Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Albany Molecular Research Inc Raises FY 2013 EPS Guidance; Issues Q4 2013 EPS Guidance In Line With Analysts' Estimates

Wednesday, 6 Nov 2013 08:00am EST 

Albany Molecular Research Inc announced that for fiscal 2013, it expects contract revenue to increase the bottom end of the range resulting in a new range of $210.5 to $213.0 million, reflecting growth at the top end of up to 12%. Adjusted diluted EPS is also updated raising the top-end of the guidance and tightening the range between $0.60 to $0.67. For the fourth quarter of 2013, the Company anticipate contract revenue between $60.0 to $62.5 million with adjusted diluted EPS expected between $0.12 and $0.19. According to I/B/E/S Estimates, analysts on an average were expecting the Company to reportEPS of $0.64 for fiscal 2013; and EPS of $0.18 for the fourth quarter of 2013. 

Company Quote

0.49 +2.63%
2:54pm EDT